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Selection of LNA-containing DNA aptamers
against recombinant human CD73†
Ida C. Elle,a Kasper K. Karlsen,a Mikkel G. Terp,b Niels Larsen,c Ronni Nielsen,d
Nicola Derbyshire,a Susanne Mandrup,d Henrik J. Ditzelbe and Jesper Wengel*a
LNA-containing DNA aptamers against CD73 (human ecto-50-nucleotidase), a protein frequently
overexpressed in solid tumours, were isolated by SELEX. A pre-defined stem-loop library, containing LNA in the
forward primer region, was enriched with CD73 binding sequences through six rounds of SELEX with
recombinant his-tagged CD73 immobilised on anti-his plates. Enriched pools isolated from rounds one, three
and six were subjected to next-generation sequencing and analysed for enrichment using custom bio-
informatics software. The software identified aptamer sequences via the primers and then performed several
steps including sequence unification, clustering and alignment to identify enriched sequences. Three enriched
sequences were synthesised for further analysis, two of which showed sequence similarities. These sequences
exhibited binding to the recombinant CD73 with KD values of 10 nM and 3.5 nM when tested by surface
plasmon resonance. Truncated variants of these aptamers and variants where the LNA nucleotides were
substituted for the DNA equivalent also exhibited aﬃnity for the recombinant CD73 in the low nanomolar
range. In enzyme inhibition assays with recombinant CD73 the aptamer sequences were able to decrease the
activity of the protein. However, the aptamers exhibited no binding to cellular CD73 by flow cytometry analysis
likely since the epitope recognised by the aptamer was not available for binding on the cellular protein.
1. Introduction
Aptamers are short oligonucleotides, usually single-stranded
and between 15 to 85 nucleotides in length. They form unique,
sequence specific, three-dimensional shapes which enable them to
bind to a wide range of targets with high specificity and aﬃnity.1–3
Aptamers are generated through Systematic Evolution of Ligands
by EXponential enrichment (SELEX), first demonstrated by the
labs of Gold4 and Szostak5 in 1990. Several variations of the
original selection strategies have been published and have
expanded the possible range of aptamer targets and improved
aptamer selectivity.6–8 Owing to their extraordinary affinity and
specificity aptamers have been dubbed ‘‘chemical antibodies’’.
They possess several advantages over traditional antibodies such
as smaller size, low immunogenicity, higher stability, potential of
renaturing, as well as easier synthesis and lower batch-to-batch
variability.9–11 However, aptamers often require chemical modifi-
cation to ensure bioavailability and biostability.11,12
LNA (Locked Nucleic Acid) is an RNA-mimic containing a
20-O,40-C-methylene bridge, which locks the furanose ring in a
C30-endo conformation.13–15 LNA nucleotides have been proven
to improve thermal stability of nucleic acid duplexes and confer
nuclease-resistance when incorporated into nucleic acid oligo-
mers.16,17 Aptamers containing LNA nucleotides by post-SELEX
modification have been reported (reviewed in16 and18), but the
effects of these modifications on aptamer function can be
difficult to predict. Therefore in investigating the properties
of LNA nucleotides in aptamers, we and others, have focused
on selecting aptamers using SELEX methods, front-loaded with
LNA and other modified nucleotides.19–23
Commercially available polymerases are capable of reading
and incorporating LNA nucleotides,22,24,25 but the eﬃcacy of
such reactions is often low. Despite this, Kasahara et al.19
recently reported the selection of aptamers containing LNA
nucleotides in the primer and the random region. They used
capillary electrophoresis and a modified SELEX protocol, which
incorporated a primer extension step in each round. Following
eleven rounds of selection, two groups of aptamer candidates
were identified by cloning and sequencing of the enriched pool.
The aptamer with the highest target aﬃnity was investigated
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further for the eﬀects of the LNA-nucleotides on its aﬃnity and
specificity. For this particular aptamer, the LNA-nucleotides were
shown to be necessary for target binding,20 but previous work from
the same group has demonstrated that this is not always the case.19
We have attempted to exploit the potential benefits of LNA
inclusion in aptamer sequences whilst maintaining a simple
SELEX protocol with good pool regeneration at the end of each
round. A library was designed containing six LNA nucleotides
in the forward primer region (Fig. 1). The design requires the
polymerase to read the modified nucleotides but not to incorpo-
rate them during library amplification. The primer regions were
partially complementary forcing formation of a 7 bp stem con-
taining two of the LNAs, while the remaining four LNAs were free
to participate in formation of other secondary structures or in
target binding (also Fig. 1). This type of library design promotes
the involvement of the primer regions in the secondary structures
and potentially in target binding. This means that post-selection
removal of primer sequences for truncation would be expected to
have detrimental consequences on the folding stability and target
binding of the aptamer sequences.
The specificity of aptamers makes them promising candidates
for targeting sub-populations of cells displaying abnormal expres-
sion levels of certain proteins; e.g. cancer cells. The ecto-50-
nucleotidase, CD73, is a GPI-anchored, homodimeric, cell surface
protein overexpressed in many solid tumours. CD73 hydrolyses
extracellular AMP to adenosine, a potent immuno-suppressor.
Therefore it has been suggested that tumour-derived CD73 is a
mediator of tumour immune-escape.27 Antibody therapy against
CD73 expressing cells inhibits breast tumour growth and meta-
stasis,28,29 while RNAi-mediated suppression of CD73 expression
induces cell-cycle arrest and apoptosis in the breast-cancer cell
line MB-MDA-231.30 An aptamer binding to cellular CD73 could
be useful as a direct inhibitor of enzymatic activity or as part of a
delivery vehicle for cytotoxic drugs to cancer cells.
Here, LNA-containing aptamers recognising recombinant
human CD73 were isolated via six rounds of SELEX coupled to
screening for sequence enrichment with next-generation sequen-
cing (NGS) and a customised bioinformatics platform. The isolated
sequences exhibited low nanomolar aﬃnity for the recombinant
protein by surface plasmon resonance (SPR) analysis, and some
also inhibited the recombinant protein’s enzyme activity. The
same was true of the truncated and modified sequences derived
from the full length aptamers. However, none of the sequences
displayed binding to cellular CD73 by flow cytometry analysis. SPRi
was utilized to partially map the aptamer–protein interaction
through a series of control and competition injections and
suggests that the binding site of the aptamer sequences is
sterically unavailable in the cellular protein.
2. Materials and methods
2.1. Oligonucleotides
The LNA-containing library, consisting of a 30 nt random region
flanked by 20 nt primer regions, and all aptamer candidates were
synthesised using an automated DNA synthesiser and standard
phosphoramidite chemistry. Aptamer candidates were synthesised
with 50-FAM and 30-biotin labels for analytical purposes. 30-Biotin-
TEG oligonucleotides were cleaved from the support matrix by
treatment with saturated ammonium hydroxide at 55 1C for 12 h.
Library purity and profile was evaluated by ion-exchange HPLC
and MALDI-MS and broad peaks were identified reflecting the
diverse library composition. LNA-containing forward primer
(50-FAM-CTCCATGACTAGAGACGTTC-3
0 LNA bases underlined)
was purchased from Exiqon A/S (Vedbæk, Denmark), and the biotin-
tagged reverse primer (50-biotin-CACAGTAGCGATACTCCATG-30)
was purchased from Sigma-Aldrich.
2.2. Proteins and antibodies
Recombinant his-tagged human CD73 for selections and bind-
ing assays was purchased from NovoProtein (C446; New Jersey
USA). His-tagged sortilin was used for negative selection steps
Fig. 1 Library design used for the selection of CD73 aptamers. Primers were designed to form a pre-determined 7 bp stem containing two LNA-T
nucleotides. Complementary regions forming this stem are underlined and LNA nucleotides are in red. The structure of the library was predicted by
Mfold26 and is shown above. LNA nucleotides are marked by red circles.
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and as a control in binding experiments. Human IgG and
lysozyme used as controls for binding assays were purchased
from Sigma-Aldrich. Recombinant N-terminal CD73 and anti-
his tag antibody were purchased from Abcam. Other antibodies
for binding assays were all commercially available, IE9 (Santa
Cruz Biotechnologies), AD2 (BD Bioscience) and IgG1 (HYP 123-05;
Bioporto).
2.3. Selection
In selection round 1, 1000 pmol of library was dissolved in 100 mL
selection buﬀer (1  PBS + 0.005% Tween 20) with 4.5 mM
MgCl2. The library was folded by incubation at 95 1C/10 min
followed by 10 min on ice. Competitor RNA, Brewer’s yeast
tRNA (Roche Applied Science), was added at a 300 fold excess to
reduce non-specific aptamer interactions. Recombinant his-
tagged CD73 (5 pmol) was immobilised on anti-his-tag plate
wells for positive selections. Negative selections were performed
by pre-incubation of the library/pool with an empty anti-his-tag
plate well for 1 h/RT/700 rpm. Positive selections were performed
by incubation of supernatant, collected from negative selections,
in CD73 coated anti his plate wells. Table 1 outlines the pro-
gression of stringency during the selections rounds which was
achieved by adjusting the ratio of library to target, number
of washes and additional negative selection steps against an
unrelated his-tagged protein, sortilin. 200 pmol of the enriched
library was used in rounds 2–6.
Competition elutions were performed in selection buﬀer
with a 10 fold excess of free CD73 compared to the immobilised
protein and incubation at 37 1C/30 min/700 rpm. Eluted pools
were amplified using KOD XL (Novagen, Merck Millipore,
Darmstadt, Germany), FAM-labelled forward primer and biotin-
labelled reverse primer in 25 cycles [98 1C/2 min followed by
25 cycles of 98 1C/15 s, 63 1C/15 s, 72 1C/1 min with a final
extension step of 72 1C/2 min]. PCR products were verified on
10% denaturing acrylamide gels. Enriched pools were regener-
ated by strand separation using Dynabeads M-280 streptavidin
(Invitrogen, Life Technologies) according to the manufacturer’s
protocol, and quantified by UV spectroscopy using a NanoDrop
2000 (Thermo Scientific).
2.4. Sequencing
Enriched pools from selection rounds one, three and six were
amplified using unmodified all-DNA primers and the PCR-
product purified from 4% agarose gels and prepared for Illumina
HiSeq 1500 sequencing according to Nielsen and Mandrup.31
Data from individual samples were sorted based on Illumina
index sequences prior to more complex bioinformatic analysis.
2.5. Bioinformatics
Sequencing datasets were analysed using BION-apta package,
custom software written by the Danish Genome Institute.
During analysis sequential steps from a ‘‘pipeline’’ or ‘‘recipe’’
are performed drawing information from files containing raw
sequences, a file defining the primers, library design, and the
random region length and a file with output table parameters.
The output from each step is input for the next and is available for
inspection after analysis. Primer sequences are used to identify the
sequences for analysis, then are cleaved resulting in a table of
random regions only. Low quality sequences are filtered out and a
maximum and minimum length filter is applied. Sequence uni-
fication collapses identical sequences into one and labels the
sequence with a read count. Similarity-based clustering, alignment
and consensus sequence extraction is then performed by the
BION-apta software before sequence grouping and small con-
served pattern discovery. This creates a reduced number of
abundance tables displaying sequences sharing a common motif,
making aptamer candidate and ‘‘family’’ discovery easier. Additional
higher-level features can be added, such as covariance-discovery and
graphics. BION-apta software also contains tools that can inter-
actively search the output tables for user-specified primary and/or
secondary structure motifs, and filter out unwanted sequences such
as primer-repeats. The recipe and the outputs are available for
download (see Availability below).
Availability. The open-source BION-apta software package
can be downloaded from: http://www2.sdu.dk/multi/bion-apta.
The results, including the workflow used, can be downloaded
from the same site.
2.6. Bio-layer interferometry
Aptamer candidates were qualitatively screened for target binding
using a BLItz (Forte´Bio) and streptavidin-covered biosensors
hydrated for 20 min in selection buﬀer before use. All binding
assays were run in the ‘‘Advanced Kinetics’’ mode with an
initial baseline of 120 s (tube), 120 s aptamer loading (drop),
120 s baseline (drop), 120 s association (drop), and 120 s
dissociation (tube). The drop holder was cleaned three times
in selection buﬀer between each step. 30-Biotin-tagged aptamer
candidates were diluted to 50 mM in selection buﬀer for
immobilisation, and recombinant his-tagged CD73 was diluted
to 1.7 mM in selection buﬀer prior to analysis.
2.7. Surface plasmon resonance
Kinetic analyses of 30-biotin-tagged aptamer candidates were
carried out on a BIAcore X100 at room temperature with a CAP
chip. Theoretical immobilisation levels yielding Rmax values of
approximately 100 RU were calculated. The aptamer candidates
were immobilised in selection buﬀer at the appropriate con-
centrations (0.025–0.1 mM) and a contact time of 60 s, except
for the shorter candidates NAC6749, NAC6788, NAC6853 and
NAC6970, which required a contact time of 180 s to yield
Table 1 Selection conditions applied to increase stringency during CD73
aptamer evolution
Round
Target : pool
ratio
Quick
washes (mL)
5 min
washes (mL) Negative selection
1 1 : 200 5  200 None Empty plate
2 1 : 40 8  200 2  200 Empty plate
3 1 : 200 4  200 1  200 Empty plate and
His-tagged sortilin
4 1 : 500 8  200 2  200 Empty plate
5 1 : 1000 4  200 1  200 Empty plate
6 1 : 1000 8  200 2  200 Empty plate and
His-tagged sortilin
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reproducible KD values. Kinetic analyses using two-fold dilu-
tions of analyte (recombinant his-tagged CD73; 0.0125–0.2 mM)
were performed at least twice for each candidate. The analyte
was injected with a flow-rate of 30 mL min1 and a contact time
of 180 s followed by 300 s dissociation. Regeneration of the CAP
chip was achieved using the manufacturer supplied buffer and
a 120 s injection. Sensorgrams were analysed and affinities
calculated using BIAevalution software.
2.8. Inhibition of CD73 enzymatic activity
Recombinant his-tagged CD73 was dissolved to 17 nM in 100 mL
of glycine buﬀer (75 mM glycine, 5 mM MgSO4, pH 7.4) contain-
ing 1 mM aptamer candidate or a,b-methylene ADP (APCP) (Sigma
Aldrich). After 1 h incubation with/without AMP at 37 1C, reac-
tions were terminated by the addition of 50 mL of 0.5 M H2SO4.
Conversion of AMP to adenosine was quantified by addition of
50 mL phosphate reaction solution (0.4% NH4-molybdate, 10%
ascorbic acid) and incubation for 30 min at room temperature.
Absorption measurements at 560 nm were acquired using a
Victor3 Multilabel Plate Reader (PerkinElmer Life Sciences).
Catalytic activity was determined by subtracting sample values
in the absence of AMP from the corresponding values in the
presence of AMP.
2.9. Flow cytometry
MDA-MB-231 cells (2  105) were harvested using scraping and
incubated in 0.05 mM aptamer or 1 mg ml1 Alexa Fluor-488
labelled anti-CD73 mAb (AD2 or 1E9) diluted in 1 PBS 0.005%
Tween 20 for 1 h at 4 1C. Following three washing steps in 1 
PBS 0.005% Tween 20 the cells were analysed by flow cytometry
using a FACScalibur (BD Bioscience). The recorded data was
analysed in Flowjo X software.
2.10. Surface plasmon resonance imaging
Serial dilutions (62.5–2000 nM) of 30-biotin-tagged aptamer candi-
dates in 50 mM sodium acetate buffer pH 4.5 were immobilised
on a G-Strep SensEye (Ssens, Enschede, The Netherlands) using
20 min contact time on a continuous flow microspotter (IBIS
technologies, Enschede, The Netherlands). Aptamer analyte
interactions spotted on SensEyes were monitored on a MX-96
SPR imager (IBIS technologies). All analytes were injected at
250 nM each. Selection buffer was used as the running and analyte
dilution buffer, association was monitored for 20 min and disso-
ciation for 30 min with a flow rate of 12 mL s1. Regeneration was
achieved using 5 M NaCl (1 min) followed by 0.5% SDS (1 min).
Sensorgrams were analysed and kinetics determined using SPRint
software.
3. Results and discussion
3.1. Aptamer evolution and identification by NGS and
bio-layer interferometry
Traditional SELEX consists of approximately ten rounds of
selection followed by cloning and sequencing of the final pool.
Typically, 50–200 bacterial clones would be randomly picked
and sequenced. Over-represented sequences would then be
synthesised and tested for binding. However, in pools that have
not been highly enriched or where significant PCR bias exists,
these numbers may prove insufficient to identify true binding
sequences. The advent of NGS technologies make it feasible to
have entire pools from multiple selection rounds analysed and
to monitor enrichment of sequences or sequence families
rather than copy number. This provides a much more complete
picture of selection progress and, in principle, a greater success
rate for identification of functional aptamer sequences.32 It has
even been demonstrated that, with the right bioinformatic
tools, it is possible to identify aptamers even after only one
round of selection.33–35
We developed custom software for the analysis of sequen-
cing data from aptamer pools. This software cleaved oﬀ primer
sequences, filtered out sequences of low quality and clustered
unique sequences. Information from the resulting sequence
tables for each pool analysed, such as sequences and read
number were used to calculate enrichment. Using the number
of reads for a unique sequence in each round and the total
number of reads in that round it was possible to calculate the
enrichment of a sequence using ordinary spreadsheet software.
We analysed selection pools 1, 3 and 6 from SELEX of a library
with a pre-defined stem-loop against the recombinant his-tagged
protein CD73. Table 2 shows the ten, overall most abundant
sequences and their enrichment factors over the course of selec-
tion. Since sequence read length was limited by reagent kits and
fell short of a full sequence read, it was necessary to identify pairs
of sequences (the complementary sequences to each other con-
verted to the same orientation) in which the central 20 nucleotides
were identical and the read counts comparable (Table 3). These
pairs of sequences were merged into a single, full length sequence
read (Table 4). Whilst this merging of shorter sequencing reads
could have been avoided by use of an extra, costly reagent kit in a
single sequencing run, the process also served as an additional
quality control step.
This analysis yielded three potentially interesting aptamer
candidates for qualitative analysis of target binding by BLItz
bio-layer interferometry. Pre-folded aptamer candidates were
immobilised on streptavidin-coated biosensors, while recombi-
nant his-tagged CD73 and his-tagged sortilin were in solution.
Both proteins exhibited no binding to empty streptavidin-coated
biosensors. One of these candidates, NAC6552, bound specifi-
cally to the recombinant his-tagged CD73. NAC6551 exhibited no
binding, and NAC6604 showed weak binding to both CD73 and
his-tagged sortilin indicating that it might bind to the his-tag of
both proteins (data not shown). Despite successful immobilisa-
tion of his-tagged CD73 on NTA biosensors, the reverse experi-
ment, protein ligand and aptamer analyte, failed to identify
binders. This is probably due to the relatively small size of the
aptamer candidates vs. CD73, a phenomenon also seen in SPR
experiments.36
The sequence of the CD73 binding aptamer, NAC6552, was
used to further filter the sequencing data from these selection
pools for sequences where the central 16 nucleotide segment was
either identical or contained a maximum of three mismatches.
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This filtering process yielded an additional aptamer candidate
(NAC6772) that resembled NAC6552 in the central region (also
shown in Tables 3 and 4). Analysis by bio-layer interferometry
showed that NAC6772 was also able to bind CD73 specifically.
The identification of candidate aptamer sequences after
selection is clearly shifting from traditional cloning and Sanger
sequencing to NGS-based approaches, and several groups have
presented methods and software for analysis of NGS-data in the
context of aptamer selection.11,32,35,37–40 Through the modifica-
tion of the files defining the primers and library our software is
applicable to all aptamer libraries. Several of the program steps
are similar to steps in the program Aptaligner published by Lu
et al.37 We believe that tandem use of NGS and well-designed
analysis software allows a much more complete evaluation of
the progress of a selection. It also enables the identification of
genuinely enriched sequences from sequences resulting from
PCR bias. The software described here is available free of charge
at http://www2.sdu.dk/multi/bion-apta. Use of NGS and the asso-
ciated bioinformatics to identify sequences of interest is limited
only in its inability to calculate functionality of said sequences.
As such it is necessary to have effective means of testing the
sequences of interest for functionality. Bio-layer interferometry
on the BLItz system appears to be a very effective means
of screening the binding capabilities of individual aptamer
candidates. The experimental demand on regents and time
for a single aptamer is extremely low vs. methods such as SPR.
Table 4 Sequence pairs and resulting aptamer candidates. Random regions are shown in bold, LNA nucleotides in red and nucleotides forming the pre-
defined stem underlined
Name Sequence pairs Aptamer candidates
NAC6551
NAC6552
NAC6604
NAC6772
Table 2 The ten most abundant sequences and their enrichment factors sorted according to total read count
Read count Enrichment factora
ID Round 1 Round 3 Round 6 Total 1–3 3–6 1–6 Sequence of random region
Total 1 084 854 125 333 53 019 1 263 206
1709 371 52 3 426 1 0 0 CGTGGGTGGGGAGGGTGGCTAGTTA
1157 222 21 0 243 1 0 0 AGCGTCGTGGGTGGGGAGGGTGGCT
1156 26 14 32 72 5 5 25 GAGAGCGCATGGACCAACGCTAGTG
1155 0 1 51 52 9 121 1044 GGGTGGGTAGGGTGGGCAGGAACGT
1154 14 17 16 47 11 2 23 CGCATGGACCAACGCTAGTGCAAGA
1153 0 1 44 45 9 104 900 CGCACCGGCATTTGTTACAGGAAGC
1152 0 0 39 39 9 92 798 CGGCATTTGTTACAGGAAGCGCGGT
1151 15 4 3 22 2 2 4 ATGCAGGGAGAATGCAGCTACCCAG
1150 0 0 18 18 9 43 368 GGTGGGTGGGCGTCTCTGTCCGGGT
1149 8 7 2 17 8 1 5 AAGCCGACTGCAGTGTGGAATGCAG
a Since it is not possible to calculate an enrichment factor from a zero read count, all zero values was substituted with one in the enrichment calculation.
Table 3 Enriched sequence aptamer pairs and their enrichment factors
Read count Enrichment factor
Pair no. ID R 1 R 3 R 6 Total 1–3 3–6 1–6 Sequence of random region (aligned)
Total 1 084 854 125 333 53 019 1 263 206
1 1156 26 14 32 72 5 5 25
1 1154 14 17 16 47 11 2 23
2 1153 0 1 44 45 9 104 900
2 1152 0 0 39 39 9 92 798
3 1155 0 1 51 52 9 121 1044
3 1183 0 0 8 8 9 19 164
4 1148 0 0 16 16 9 38 327
4 1145 0 0 8 8 9 19 164
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With just a few mL of low mM aptamers and targets it is possible
to discern the potential of an aptamer candidate in less than
15 minutes. However, with no automation, testing of batches of
aptamer candidates can become tedious and time-consuming
compared to more high throughput methods such as SPRi
described below.
3.2. Folding and truncation
Following the successful identification of two binding sequences
with high sequence homology, secondary structure predictions by
Mfold26 were used to compile a selection of truncated sequences
that maintained or partially maintained similar secondary struc-
tures in the random region (Fig. 2).
Despite such sequence similarity the most favourable pre-
dicted fold for NAC6552, the originally identified sequence, was
somewhat diﬀerent to that of NAC6772 (Fig. 3). However, it was
not surprising to see that it was possible for NAC6772 to also
form a secondary structure that produced a similar stem-bulge-
stem-loop, with only three bases in the loop section diﬀering.
Fig. 2 shows this more similar secondary structure in an attempt
to illustrate the rationale for the specific truncations tested.
NAC6746, NAC6747, NAC6749 and NAC6748 were composed of
the random region of NAC6552 and gradually reduced primer
regions. Likewise, NAC6853 was a truncation of the primers from
NAC6772. The remaining candidates depicted were attempts to
alter the loop of the secondary structures to partially define bases
essential for target binding.
The conformational changes in an aptamer’s secondary and
tertiary structures that may be induced on target binding make
Fig. 2 Secondary structure predictions and KD values for CD73 binding aptamers and derived truncations. NAC6552 and NAC6772 were truncated step-by-step
as indicated by the arrows and secondary structures predicted by Mfold.26 LNA nucleotides are marked by red circles. All-DNA versions of NAC6552, NAC6749,
NAC6772, and NAC6853 are not shown but indicated by sequence number. ‘‘*’’ indicates that KD values could not be determined for this aptamer.
Fig. 3 Most favorable secondary structure predictions for NAC6772/
NAC6750 (with and without LNA bases, respectively) and its truncated
version NAC6853/NAC6970 suggested by Mfold.26 LNA nucleotides are
marked by red circles.
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it diﬃcult to predict which bases and structures formed by a
particular sequence are necessary for functionality. Despite this,
secondary structure predictions often provide a useful starting
point when considering truncation and mutation sites. Here,
with the help of these predictions, we were able to make strategic
modifications (truncations and LNA to DNA nucleotide substitu-
tions) to the two CD73 binding sequences.
3.3. Surface plasmon resonance
Aptamer-target kinetics for all candidates were determined with
SPR using a BIAcore X100. Aptamers were tested in the order
that they were designed and the KD values are provided in
Table 5. This permitted monitoring of the minimum length of a
functional CD73 aptamer derived from the two original binding
sequences (NAC6552 and NAC6772) and the necessity of the
loop region in the secondary structure predictions. Substitution
of LNA nucleotides with the DNA equivalents were analysed to
determine if LNA was integral to CD73 binding.
The KD value of the parent aptamer candidate NAC6552 was
9.9  0.04 nM. A minor truncation to NAC6552 of the 13
nucleotide 30 ‘‘tail’’ of the reverse primer region (resulting
sequence NAC6746) improved the KD slightly to 6.5  0.79 nM.
NAC6747, further reduced by five nucleotides in the 50 and 30
regions performed equally well to the parent aptamer with a KD
value of 9.3  0.04 nM. However, further truncation, removing
all of the reverse primer and leaving only the last six nucleotides
of the forward primer (sequence NAC6749) had a slightly detri-
mental eﬀect of the KD 15.4  0.35 nM. The final truncation,
where NAC6552 was reduced to 26 nucleotides of the random
region, lead to a molecule (NAC6748) which was unable to bind
CD73 in SPR assays.
The KD value of parent sequence NAC6772 was 3.54 0.59 nM.
A truncated variant of this (NAC6853), similar in design to
NAC6749 was determined to have a KD of 12.5  1.14 nM
suggesting that truncation of this particular sequence was
tolerated to approximately the same extent as for NAC6552
and therefore further truncations were not tested.
Reduction of the loop region of the shortest functional variant
of NAC6552, in sequences NAC6854 and NAC6789 eradicated
CD73 binding. Whilst substitution of the LNA nucleotides with
the DNA equivalent in both the parent strands (NAC6552 and
NAC6772) and the shortest functional variants of these (NAC6749
and NAC6853, respectively) retained comparable CD73 binding.
Data showed the KD of the all DNA version of NAC6552 to be
5.48  0.04 nM vs. 9.94  0.07 nM and the KD of the all DNA
version of NAC6772 to be 4.04  0.28 nM vs. 3.54  0.59 nM.
Data also showed the all DNA version of NAC6749 to have a KD
of 13.20  1.84 nM vs. 15.40  0.34 nM and finally the all DNA
version of NAC6853s KD to be 19.00 0.94 nM vs. 12.50 1.14 nM.
This final variant did behave somewhat diﬀerently to the other
sequences during SPR requiring higher aptamer concentrations
(0.1 mM compared to 0.025 mM) to achieve the appropriate
response levels. This indicated that the actual capture level may
have deviated from the calculated one. It is possible that the
secondary structure of this aptamer required for CD73 binding
is less stable than for other candidates and therefore higher
immobilisation concentrations are required to produce the
suﬃcient response level.
Collectively, these aﬃnity experiments suggest that only
small parts of the primer regions adjacent to the random region
and the loop seen in secondary structure predictions are
requirements for CD73 binding. We hypothesise that whilst
the loop forms the majority of aptamer–target interactions, the
primer region stabilises the formed structure. The results also
demonstrated that despite the design of the library to promote
LNA involvement in the binding regions, LNA were not funda-
mental for target binding with very little difference in affinity
seen when substituting LNA for DNA. They also show that only
a minimal part of the 30-end of the forward primer was required
to keep the functionality intact. This finding is in line with the
findings of Kasahara et al. who saw that target affinity was
improved for certain structural motifs and reduced for others
when a DNA-primer was replaced with an LNA-containing version
for aptamer production.19,20 Similarly, we have found that single
LNA nucleotide substitutions in an avidin-binding DNA aptamer
can significantly impact aptamer binding.41
3.4. Inhibition of CD73 enzymatic activity
To elaborate on the binding results, the enzymatic inhibition of
recombinant his-tagged CD73 by the aptamer candidates was
measured. The AMP-mimic, APCP, was used as a positive control
of inhibition and sample readings (CD73 plus aptamer and AMP)
were normalized against background signals (CD73 plus aptamer).
A560 readings of CD73  aptamers were used to calculate the
percentage inhibition. Binding aﬃnity does not always correlate
with inhibitory eﬀect, so it is not possible to accurately quantitate
aﬃnity based on inhibition. However, with all except one aptamer
candidate (NAC6748) the enzymatic activity of the recombinant
CD73 was reduced in the presence of aptamers proven to bind by
bio-layer interferometry and SPR (Table 5).
NAC6748 was an interesting case. This was the shortest aptamer
candidate synthesised and CD73 binding was not detectable by bio-
layer interferometry or SPR. The fact that it was able to inhibit the
activity of CD73 to a similar level to sequences seen to bind by SPR
suggests that it forms a similar interaction with CD73 to its longer
counter parts. This postulates the question of why binding was not
observed in earlier assays. It is possible that in ligand immobilised
assays with such short aptamers the aptamer–target interaction
could be sterically hindered by the proximity of the binding region
to the capture surface. This could be confirmed by synthesis of the
short sequence with a spacer prior to the biotin but this was not
performed here.
3.5. Binding of cellular CD73 by aptamer candidate measured
by flow cytometry
Flow cytometry was utilized to investigate whether the aptamer
candidates were able to bind to CD73 expressed on live cells
(MDA-MB-231 human breast cancer cells). None of the 17
aptamers showed any binding to CD73 on live breast cancer
cells when compared to the negative control aptamer NAC6551
(Fig. 4A–C). Aptamer NAC6748, shown as non-binding in the
affinity analysis although inhibiting the enzymatic activity of
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recombinant CD73, also showed no binding to CD73 on breast
cancer cells (Fig. 4D).
In light of this finding the enzymatic assay was repeated
replacing the recombinant his-tagged CD73 with MDA-MB-231
cells. Unfortunately, no inhibition of the cellular protein’s activity
was seen with any of the aptamer candidates (data not shown),
including NAC6748.
When trying to isolate aptamers against cellular proteins,
compromises in the SELEX process are sometimes necessary.
Direct selection against cellular proteins is possible42–45 but is
challenging due to the complexity of cell surfaces and requires
access to cell culture facilities. Using a purified recombinant
protein as the target is a compromise. It simplifies the selection
process but creates potential for evolution of aptamers that
bind to parts of the protein that may be sterically unavailable in
the cellular form. In this case, cellular CD73 is a GPI-anchored,
cell-surface protein that forms a homodimer through non-covalent
bonds,46 whilst the recombinant protein is a his-tagged protein
expressed as a monomer without the GPI-anchor. This recombi-
nant CD73 may or may not remain as a monomer after purifica-
tion. Areas of CD73, such as the region around the GPI-anchor,
near the cellular surface, may be inaccessible in the cellular vs.
recombinant form. This may be the reason why we observed no
binding of the aptamers to cellular CD73 in flow cytometry or
inhibition of cellular CD73 activity. Though in this work a focus
was on the technical aspects of the SELEX process and therefore
only recombinant CD73 was used as the target for selection, we
were interested to partially map the binding of the aptamer
candidates to CD73 and utilised a series of analyte competition
injections and SPRi to do so.
Table 5 CD73 aptamer candidates’ aﬃnities and enzyme inhibition activity. LNA-nucleotides are shown in red, random regions in bold and the pre-
defining stem nucleotides are underlined. All aptamer candidates were synthesised with 50-FAM and 30-biotin labels. ‘‘n.b.’’ indicates no binding
Library Sequence (50–30)
NAC5613 — —
Candidate Sequence
KD
a
(nM)
%
Inhibition
NAC6551 n.b. 6.7
NAC6552 9.94  0.07 81.0
NAC6552 all-DNA 5.48  0.04 93.8
NAC6604 n.b. 41.9
NAC6746 6.47  0.79 71.9
NAC6747 9.29  0.04 76.2
NAC6749 15.40  0.35 65.2
NAC6788 all-DNA 13.20  1.84 79.5
NAC6748 all-DNA n.b. 77.1
NAC6789 n.b. 39.5
NAC6801 n.b. 21.4
NAC6772 3.54  0.59 85.2
NAC6750 all-DNA 4.04  0.28 65.7
NAC6853 12.50  1.14 83.3
NAC6970 all-DNA 19.00  0.94 79.0
NAC6852 all-DNA n.b. 29.0
NAC6854 n.b. 11.4
a Kinetic analyses were performed in at least duplicates and mean  standard deviation is shown. Enzyme inhibition activity of recombinant CD73
was determined colorimetrically and normalized to background levels (no AMP present) for each candidate. A560 values of CD73 alone and with
each aptamer were used to derive percentage inhibition values.
Fig. 4 Flow cytometry analysis of aptamer binding to MDA-MB-231 breast
cancer cells. (A) Each point represents the logarithm-transformed values of
the geometric mean of the signal intensity from flow cytometry analysis of
each of 17 diﬀerent CD73 aptamers and two anti-CD73 mAb (AD2 and 1E9).
Points representing unstained cells and cells stained with aptamer NAC6748,
NAC6551, NAC6746 and anti-CD73 mAb AD2 and 1E9, respectively, are
specified. (B–D). Staining profile of aptamers (NAC6746, NAC6551, NAC6748,
respectively, gray tinted), unstained (black dashed), 1E9 (black solid line) and
AD2 (black dotted line) on MDA-MB-231 cells.
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3.6 Aptamer–target interaction mapping and specificity by
SPR imaging
SPRi was employed to verify the specificity of the aptamer
candidates and attempt to narrow down the region of the
protein the aptamers bind to. KD values for the aptamer–target
interactions determined by SPRi were comparable to those
determined by SPR (ESI,† Table S1). None of the aptamer
candidates, with the exception of NAC6604 discussed
previously, exhibited binding to the other proteins tested
(lysozyme, thrombin, streptavidin and his-tagged sortilin)
indicating that the aptamers were in fact specific for CD73
(Table S1, ESI†).
No aptamer binding of AMP was observed and co-injection of
CD73 with AMP showed no reduction in aﬃnity of the aptamer
candidates (example shown in Fig. 5). This would indicate that
the aptamers do not bind directly to CD730s active site, which is
in the C-terminal portion of the protein, but instead inhibit the
enzymatic activity by changing the conformation of the protein
or limiting the conformational change required for activity.
It was expected that when performing co-injections of CD73
and anti-CD73 antibodies (AD2 and IE9) and negative control
antibodies (human IgG, IgG1 and anti-his tag), that competitive
binding would knock out binding. However, non-competitive
binding would lead to an increased response owning to the
larger analyte (protein plus antibody) but the KD would remain
unchanged. None of the aptamers bound competitively to the
AD2 binding site but it was not possible to comment on the
interaction with IE9 owning to a buﬀer response obscuring
the picture (Fig. 5). The negative controls also had no eﬀect on
binding of CD73. These data indicate that the aptamers bind
recombinant his-tagged CD73 in regions distal to the antibodies
which can bind cellular or recombinant CD73.
Finally, none of the aptamer candidates bound to a recom-
binant N-terminal CD73 fragment indicating that the aptamer
candidates bound CD73 in the C-terminal domain of the protein.
Fig. 5 Partial NAC6552 aptamer-CD73 mapping by SPRi. (A) Sensorgrams of negative control injections. Buﬀer, AMP, lysozyme, his-tagged sortilin,
CD73 binding antibodies (AD2 and IE9), anti-his tag antibody and non-CD73 binding antibodies (IgG1 and human IgG) showed no interaction with the
immobilised aptamers. (B) Sensorgrams of competition injections. Aptamers showed specificity for CD73 but not the N-terminal portion of CD73 and did
not bind competitively with any of the antibodies shown in (A) or AMP. (C) Summary table of SPRi injections, aﬃnities and conclusions. Binding sensitivity
changed only slightly between the co-injections of potentially competitive analytes (15.1–24.0 nM) and the CD73 alone (16.8 nM).
Molecular BioSystems Paper
O
pe
n 
A
cc
es
s A
rti
cl
e.
 P
ub
lis
he
d 
on
 1
7 
Fe
br
ua
ry
 2
01
5.
 D
ow
nl
oa
de
d 
on
 0
7/
07
/2
01
6 
08
:4
4:
02
. 
 
Th
is 
ar
tic
le
 is
 li
ce
ns
ed
 u
nd
er
 a
 C
re
at
iv
e 
Co
m
m
on
s A
ttr
ib
ut
io
n 
3.
0 
U
np
or
te
d 
Li
ce
nc
e.
View Article Online
This journal is©The Royal Society of Chemistry 2015 Mol. BioSyst., 2015, 11, 1260--1270 | 1269
In cellular CD73, the GPI-anchor is at the C-terminal meaning
that part of the C-terminal domain will be in contact with the
cell surface and unavailable for binding. Further to this it is the
C-terminal that is involved in formation of the cellular homo-
dimer protein possibly restricting aptamer access.
Without complicated structural analysis of the recombinant
his-tagged CD73 complexed with a binding aptamer candidate
by crystallography or NMR it is impossible to discern the actual
binding site. Doing so could determine the reason why the
CD73 aptamer candidates were able to bind and inhibit the
recombinant but not the cellular form of the protein. However,
by using SPRi it has been determined that the aptamers bind to
the C-terminal domain and within this domain we know that
significant portions of the protein are occupied by interactions
with the cell surface or protein dimerization which could hinder
aptamer–target interactions.
4. Conclusions
Aptamers containing LNA nucleotides were selected against
recombinant human CD73 using SELEX and NGS with custom
NGS bioinformatics software. Two similar sequences where
identified that bind CD73 with high aﬃnity and good specificity.
Several truncated and modified versions of these aptamers, the
shortest of which was 34 nts, were shown to also bind to the
target with low nanomolar aﬃnities. It was shown that the LNA
nucleotides had little impact on aptamer aﬃnities but that
reduction of the loop section predicted by Mfold was extremely
detrimental to CD73 binding. These CD73 aptamers were also
able to inhibit the enzyme activity of recombinant CD73, but were
ineﬀective against cellular CD73 in the same assay and showed
no binding during flow cytometry. These aptamers were shown to
bind to the C-terminal domain of CD73 which may go some way
to explain their lack of function with cellular CD73. Despite their
lack of aﬃnity for cellular CD73, these aptamers could find a use
in research or as a capture agent in the purification of recombi-
nant CD73. This work presents the first example of aptamers
against CD73, the first evolution of LNA-containing aptamers
selected using traditional SELEX, introduces the BION-apta soft-
ware as a highly flexible tool for analyzing NGS data in the context
of aptamer evolution, and introduces SPRi as a tool of partial
mapping of aptamer binding sites.
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